Innovation Pharmaceuticals Inc. carries a market capitalization of 1.04M, placing it among publicly traded companies globally. Its enterprise value stands at 5.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.04M |
| Enterprise Value | 5.45M |
Innovation Pharmaceuticals Inc. currently has 518.35M shares outstanding.
| Shares Outstanding | 518.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.05 |
| P/TBV Ratio | -8.16 |
| P/FCF Ratio | -3.05 |
| P/OCF Ratio | -3.05 |
Innovation Pharmaceuticals Inc. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.48, indicating elevated leverage, while an interest coverage ratio of -35.45 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.19 |
| Quick Ratio | 0.17 |
| Debt / Equity | 20.48 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -35.45 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -32.74 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Innovation Pharmaceuticals Inc.'s stock has gained approximately 566.66667% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 566.66667% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
EBITDA reached -1.98M, while operating income came in at -2.36M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.36M |
| Pretax Income | -2.62M |
| Net Income | -2.62M |
| EBITDA | -1.98M |
| EBIT | -2.36M |
| Earnings Per Share (EPS) | -0.01 |
Innovation Pharmaceuticals Inc. holds 864,000.00 in cash and equivalents against 238,000.00 in total debt, resulting in a net debt position of -626,000.00. Total book value stands at -126.15M, with working capital of -4.11M providing operational flexibility.
| Cash & Cash Equivalents | 864,000.00 |
| Total Debt | 238,000.00 |
| Net Debt | -626,000.00 |
| Equity (Book Value) | -126.15M |
| Book Value Per Share | -0.25 |
| Working Capital | -4.11M |
Innovation Pharmaceuticals Inc. produced -1.99M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.99M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.99M |
| FCF Per Share | 0.00 |
The company's payout ratio of -1.83 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -1.83 |
| Shareholder Yield | 0.89 |
| FCF Yield | -32.78 |
Innovation Pharmaceuticals Inc. posts an Altman Z-Score of -39.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -39.13 |